1
|
Satanova A, Bolatbekova R, Kukubassov Y, Ossikbayeva S, Kaidarova D. Vaccination Effectiveness against Human Papillomavirus in Kazakhstan. Asian Pac J Cancer Prev 2024; 25:681-688. [PMID: 38415556 PMCID: PMC11077137 DOI: 10.31557/apjcp.2024.25.2.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 02/16/2024] [Indexed: 02/29/2024] Open
Abstract
OBJECTIVE The purpose was to determine the effectiveness of human papillomavirus immunization and its impact on cervical cancer development in Kazakhstan. METHODS The current research is a case-control study with two groups: a main group and a control group. A total of 725 subjects participated in the research. RESULTS The association between vaccination and cervical cancer development was calculated both for the two groups as a whole and for individual patients, who were selected based on criteria of residence, presence of immunodeficiency or chronic cardiac or renal pathology, as well as analysis of age at which the vaccine dose was received. There was a statistically significant association between the absence of the human papillomavirus vaccine and the risk of cervical cancer in all groups. When considering the entire cohort, the chance of finding a risk factor (lack of vaccination) was almost 7 times higher in the main group than in the control group. Thus, an association between vaccination and cervical cancer risk was found in each of the pairs of subjects. CONCLUSION The effectiveness of vaccination in preventing cervical cancer was not observed in patients who were vaccinated after 18 years of age, while most patients in the control group were vaccinated in their teens. The practical significance of the research is not only to further study the problem of human papillomavirus (HPV) vaccination in Kazakhstan but also to popularize HPV immunization to prevent cervical cancer (CC).
Collapse
Affiliation(s)
- Alima Satanova
- Oncogynecological Center, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.
| | - Raikhan Bolatbekova
- Oncogynecological Department, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.
| | - Yerlan Kukubassov
- Oncogynecological Center, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.
| | - Saniya Ossikbayeva
- Centre for Molecular Genetic Research, Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.
| | - Dilyara Kaidarova
- Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan.
| |
Collapse
|
2
|
Bolatbekova R, Kaidarova D, Dushimova Z, Shatkovskaya O, Zhylkaydarova A, Kukubassov Y, Sadykova T, Satanova A, Bertleuov O, Kaldybekov D. Prevalence of HPV and cytological abnormalities in young women in Almaty, Kazakhstan. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e22503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22503 Background: Cervical cancer (CC) is the second most common type of cancer for women worldwide. 99% of cases of CC are associated with high-risk human papillomaviruses (HPV HR). Unfortunately, data on the epidemiology of HPV in Kazakhstan are limited, especially in young kazakhstani women. This study was provided to determine the prevalence of HPV HR and the cytological abnormalities in young Kazakhstani women, which will allow strengthening control in the existing CC screening in this age. Methods: 101 women aged 18-30 years were invited to this cross-sectional study. Women were mentally healthy and did not have a positive human papillomaviruses (HPV) history. Cervical samples for HPV were analyzed with using of Cobas 4800 HPV test. Cytological examination of smears with using the Bethesda terminology system and HPV test were conducted at Kazakh Institute of Oncology and Radiology. Results: The mean age of the study group was 21.0±2.8 years (range 18-30 years). Prevalence of HPV was 11,8% (12 cases). HPV 16 and 18 were the most common type in analyzed cases (5,9%). Cytological abnormalities occurred in 19,8% (20 cases). The Mann-Whitney test of the frequency of cytological abnormalities showed that the ASCUS and LSIL was significantly more found in the group up to 25 years. The HSIL was more common in a group of women 25 years and older and accounted for 1.9 % out of 2 cases (p < 0.05). Conclusions: The results of this study confirm the need for HPV vaccination of adolescent girls and improvement of the existing screening through the inclusion of women to screening from 25 years of age. Changing of CC screening through implementation of HPV screening with cytological triage of HPV - positive of women can reduce the burden of CC in young age in KazakhstanPrevalence of high risk HPV and cytological abnormalities in young women in Almaty, Kazakhstan.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Tolkyn Sadykova
- Kazakh Institute of Oncology and Radiology, Akmaty, Kazakhstan
| | - Alima Satanova
- Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| | | | | |
Collapse
|
3
|
Bolatbekova R, Kaidarova D, Zhylkaidarova A, Sadykova T, Kukubassov Y, Satanova A, Aidarov A. Cervical cancer screening: Twelve years experience of the Kazakhstan National Screening program. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e17520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17520 Background: Cervical cancer (CC) is the most common gynecological cancer in Kazakhstan (KZ). Standardized incidence rate of CC was 16.7 per 100, 000, while the mortality rate was 5, 9 per 100, 000, in 2020. The National Cervical Screening program in KZ uses cytology (Pap test) from 2008, which is free of charge for women aged 30 to 70 years of age with an interval of 4 years. In 2017 Experts from ImPact Mission and analyzed existing CC screening revealed a number of recommendations aimed at reducing the screening interval and increasing the coverage. The purpose of this study was to analyze results of CC screening in KZ and his impact on CC incidence and mortality. Methods: Coverage, the number of screened women, the level of pre-cancer detection and cervical cancer during screening have been obtained from specific reports (form № 025, № 08) for 2008-2020. Results: The total number of screened women for 2008 were 554 283 women. There is a decrease in screening coverage to 45.9% in 2017 due to a decrease in funding. in this regard, in 2017, a number of changes were made to the existing screening program. In 2020 after the CC screening improvement 786 690 women were examined during the screening program, coverage rate was 66, 2%, . Analysis of screening results showed a marked increase in the detection of precancerous lesion from 0, 136 in 2008 to 0, 87 with an increasing by 37%. The analysis of CC incidence revealed significant changes: after the introduction of screening, an increase in the incidence rate is noted from 15.5 in 2008 to 20.1 per 100, 000 female population in 2015. Since 2015, there has been a significant decrease to 16.7 per 100, 000 women. Conclusions: Despite the positive results of screening, an increse the screening coverage, improvement in the detection of the initial stage of CC, mortality rate from CC and a one-year mortality remain high, which makes it necessary to improve the screening of CC in KZ through the introduction of HPV-screening
Collapse
Affiliation(s)
| | | | | | - Tolkyn Sadykova
- Kazakh Institute of Oncology and Radiology, Akmaty, Kazakhstan
| | | | - Alima Satanova
- Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| | - Askar Aidarov
- Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| |
Collapse
|
4
|
Lanner M, Nikolova T, Gutic B, Nikolova N, Pletnev A, Selcuk I, Vlachos DE, Razumova Z, Bizzarri N, Theofanakis C, Lepka P, Kahramanoglu I, Han S, Nasser S, Molnar S, Hudry D, Montero-Macías R, de Lange N, Macuks R, Hasanov MF, Karimbayli R, Gagua I, Andrade C, Pardal C, Dotlic J, Alvarez RM, Hruda M, Fruhauf F, Ekdahl L, Antonsen SL, Sukhin V, Eriksson AGZ, Gliozheni E, Delic R, Satanova A, Kovacevic N, Gristsenko L, Babloyan S, Zalewski K, Bharathan R. Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists. Int J Gynecol Cancer 2020; 31:575-584. [PMID: 33361458 DOI: 10.1136/ijgc-2020-002176] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/14/2020] [Accepted: 12/16/2020] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND ESGO (European Society of Gynaecological Oncology) and partners are continually improving the developmental opportunities for gynaecological oncology fellows. The objectives of this survey were to evaluate the progress in the infrastructure of the training systems in Europe over the past decade. We also evaluated training and assessment techniques, the perceived relevance of ENYGO (European Network of Young Gynaecological Oncologists) initiatives, and unmet needs of trainees. METHODOLOGY National representatives of ENYGO from 39 countries were contacted with an electronic survey. A graduation in well/moderately/loosely-structured training systems was performed. Descriptive statistical analysis and frequency tables, as well as two-sided Fisher's exact test, were used. RESULTS National representatives from 33 countries answered our survey questionnaire, yielding a response rate of 85%. A national fellowship is offered in 22 countries (66.7%). A logbook to document progress during training is mandatory in 24 (72.7%) countries. A logbook of experience is only utilized in a minority of nations (18%) for assessment purposes. In 42.4% of countries, objective assessments are recognized. Trainees in most countries (22 (66.7%)) requested additional training in advanced laparoscopic surgery. 13 (39.4%) countries have a loosely-structured training system, 11 (33.3%) a moderately-structured training system, and 9 (27.3%) a well-structured training system. CONCLUSION Since the last publication in 2011, ENYGO was able to implement new activities, workshops, and online education to support training of gynaecological oncology fellows, which were all rated by the respondents as highly useful. This survey also reveals the limitations in establishing more accredited centers, centralized cancer care, and the lack of laparoscopic training.
Collapse
Affiliation(s)
- Maximilian Lanner
- Department of Obstetrics and Gynaecology, Kardinal Schwarzenberg Klinikum, Schwarzach im Pongau, Austria
| | - Tanja Nikolova
- Klinikum Mittelbaden, Academic Teaching Hospital of Heidelberg University, Baden-Baden, Germany
| | - Bojana Gutic
- Gynaecology Department, Vojvodina Institute of Oncology, Sremska Kamenica, Serbia
| | - Natasha Nikolova
- Department of Obstetrics and Gynaecology and Centre for Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy
| | - Andrei Pletnev
- Department of Gynaecological Oncology, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | - Ilker Selcuk
- Gynaecological Oncology, Maternity Hospital, Ankara City Hospital, Ankara, Turkey
| | - Dimitrios-Efthymios Vlachos
- First Department of Obstetrics and Gynaecology, National and Kapodistrian University of Athens, Athens, Greece
| | - Zoia Razumova
- Department of Women's and Children's Health, Division of Neonatology, Obstetrics and Gynaecology, Karolinska Institute, Stockholm, Sweden
| | - Nicolò Bizzarri
- UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy
| | - Charlampos Theofanakis
- Department of Gynaecological Oncology, General Hospital of Athens Alexandra, Athens, Attica, Greece
| | - Piotr Lepka
- Department of Oncology, Gynaecological Oncology Clinic, Wroclaw Medical University and 2nd Lower Silesian Oncology Centre, Wroclaw, Poland
| | - Ilker Kahramanoglu
- Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Istanbul University Cerrrahpasa Medical Faculty, Istanbul, Turkey
| | - Sileny Han
- Gynaecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium
| | - Sara Nasser
- Department of Gynaecological Oncology, Gynaecology Clinic with Oncologic Surgery Centre, Charité Comprehensive Cancer Centre, Campus Virchow Klinikum, Berlin, Germany
| | - Szabolcs Molnar
- Department of Obstetrics and Gynaecology, University of Debrecen Faculty of Medicine, Debrecen, Hungary
| | - Delphine Hudry
- Department of Gynaecological Oncology, Centre Oscar Lambret, Lille, France
| | - Rosa Montero-Macías
- Gynaecologic and Breast Oncologic Surgery Department, European Hospital Group Georges-Pompidou, Paris, France
| | - Natascha de Lange
- Department of Gynaecological Oncology, Universitair Medisch Centrum Groningen, Groningen, Netherlands
| | - Ronalds Macuks
- Department of Obstetrics and Gynaecology, Riga Stradins University, Riga, Latvia
| | - Mir Fuad Hasanov
- Department of Obstetrics and Gynaecology, Medical Center-University of Freiburg, Freiburg, Baden-Württemberg, Germany
| | - Ramina Karimbayli
- Department of Oncogynaecology, The National Centre of Oncology, Baku, Azerbaijan
| | - Irina Gagua
- Department of Gynaecology, Research Institute of Clinical Medicine, Todua Clinic, Tbilisi, Georgia
| | - Claudia Andrade
- Department of Gynaecology, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal
| | - Catarina Pardal
- Department of Obstetrics and Gynaecology, Hospital de Braga, Braga, Portugal
| | - Jelena Dotlic
- Clinic of Obstetrics and Gynaecology, Clinical Centre of Serbia, University of Belgrade, Beograd, Serbia
| | - Rosa Maria Alvarez
- Department of Gynaecological Oncology and Breast Cancer, Santa Cristina University Hospital, Madrid, Spain
| | - Martin Hruda
- Department of Obstetrics and Gynaecology, 3rd Medical Faculty, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Filip Fruhauf
- Department of Obstetrics and Gynaecology, General University Hospital, Charles University, Prague, Czech Republic
| | - Linnea Ekdahl
- Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Skåne University Hospital Lund, Lund, Sweden
| | - Sofie Leisby Antonsen
- Gynaecological Department, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Vladyslav Sukhin
- Department for Gynaecological Oncology, Grigoriev Institute for medical Radiology and Oncology NAMS, Kharkov, Ukraine
| | - Ane Gerda Zahl Eriksson
- Department of Gynaecological Oncology, Division of Cancer Medicine, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - Elko Gliozheni
- Department of Obstetrics and Gynaecology, Maternity Koco Gliozheni Hospital, Tirana, Albania
| | - Ratko Delic
- Department of Obstetrics and Gynaecology, General Hospital Celje, Celje, Slovenia
| | - Alima Satanova
- Department of Gynaecological Oncology, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| | - Nina Kovacevic
- Department of Gynaecological Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - Liidia Gristsenko
- Department of Obstetrics and Gynaecology, The North Estonian Medical Centre, Tallinn, Estonia
| | - Suzanna Babloyan
- Department of Obstetrics and Gynaecology, Yerevan State Medical University, Yerevan, Armenia
| | - Kamil Zalewski
- Gynaecological Oncology, Świętokrzyskie Cancer Centre, Kielce, Poland
| | - Rasiah Bharathan
- Department of Gynaecological Oncology, Maidstone Hospital, Maidstone, Kent, UK
| |
Collapse
|
5
|
Kaidarova D, Bolatbekova R, Zhylkaidarova A, Sadykova T, Kukubassov Y, Aidarov A, Satanova A. Opportunities and challenges in cervical cancer screening program in Kazakhstan: Results after imPACT review. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e18020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18020 Background: Cervical cancer is the second most common cancer in women worldwide, where the majority of registered patients are in developing countries. Screening programs in developed countries have reduced morbidity and mortality from cervical cancer by more than 2 times. Cervical cancer (CC) is the most common gynecological cancer in Kazakhstan (KZ). Standardized incidence rate of CC was 18.2 per 100,000, while the mortality rate was 6.2 per 100,000, in 2019. The National Cervical Screening program in KZ uses cytology (Pap test) from 2008. Screening program funded by the State budget. In 2016, Experts of imPACT Mission analyzed the CC screening and made recommendations for improvement. Since 2018 target age of CC screening expanded to 30-70 years and shortened the interval to 4 years, strengthened the control of patients with pre-cancerous pathology. Until 2018, people came to a fixed age; today we start CC screening within the target age at any age at the time of the first visit. The purpose of this study is to analyze cytological screening results in KZ after imPACT recommendations. Methods: Coverage, the number of screened women, the level of pre-cancer detection and cervical cancer during screening have been obtained from specific reports (form № 025, № 08) for 2008-2019. Results: The total number of screened women was in 6.775.975. There is a decrease in the number of screened women by 32% from 2008 to 2017. Since improvement of CC screening we increased coverage from 49.9% in 2017 (abs. number 409.124) to 89% in 2019 (abs. number 954.322). According to the results of screening, 2603 cases of CC were registered in 12 years. Analysis of screening results showed a marked increase in the detection of CC with an increasing by 67%. The persentage of registered cases of ASH+HSIL increased from 0.136% to 0.673%. Conclusions: there has been an increase in the coverage by screening of the target population since the screening update. During the study period, there has been an improvement in the detection of precancerous pathology and cancer in the early stage. Despite the positive results of screening, sufficient coverage by screening, certain successes in detecting the initial stage of CC, mortality rate from CC remain high, which makes it necessary to improve the screening of CC in KZ through the introduction of HPV-screening.
Collapse
Affiliation(s)
| | | | | | - Tolkyn Sadykova
- Kazakh Institute of Oncology and Radiology, Akmaty, Kazakhstan
| | | | - Askar Aidarov
- Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| | - Alima Satanova
- Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
| |
Collapse
|